Mayne Pharma Group (MYX) Short Interest
Mayne Pharma Group (ASX:MYX) had 2.27% of shares reported as short positions as of 24 Aug 2026, representing 1,841,670 shares. Mayne Pharma Group operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Mayne Pharma Group
Mayne Pharma Group Limited is a specialty pharmaceutical company listed on the ASX, focused on commercializing pharmaceuticals and improving patient access to life-enhancing medications. The company has a 40-year track record of innovation in developing oral drug delivery systems, offering a portfolio of branded and generic drugs in therapeutic areas like women's health and dermatology.
Short position
Mayne Pharma Group (ASX:MYX) has 2.27% of its shares on issue reported as short positions as of 24 Aug 2026, or about 1,841,670 shares. Over the past 30 days that figure has fallen 0.11 percentage points, and over 90 days it has fallen 0.69 percentage points. Its highest recorded short interest was 13.44% in May 2017. MYX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4MYX intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Mayne Pharma Group
Latest MYX news
All newsAbout
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss MYX
Start a research thread or post the first pulse update